For laboratory research use only. This page summarizes public scientific literature. It is not medical advice and does not describe or endorse human, clinical, or veterinary use.
Chemistry & identity
| CAS Number | 1415456-99-3 |
|---|---|
| Molecular Formula | C194H312N54O59S2 |
| Molecular Weight | 4409 g/mol |
| PubChem CID | 171397054 |
Peptide sequence
n.a.
Research context
PubChem and DrugBank (DB18887) list no explicit amino-acid sequence; only a systematic name with an ambiguous residue numbering (cyclic 3->8 disulfide). Sequence and residue count left n.a. rather than inferred.
Selected research references
Published peer-reviewed literature on Cagrilintide. Provided for research-context purposes only; CC Peptides does not make claims about outcomes in humans.
- Development of Cagrilintide, a Long-Acting Amylin Analogue
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
Cagrilintide for laboratory research
CC Peptides supplies Cagrilintide as a lyophilized reference material with a third-party COA. Ships from California.
View product page →